Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia

Cristina Tanaseanu, Slobodan Milutinovic, Petre I. Calistru, Janos Strausz, Marius Zolubas, Valeriy Chernyak, Nathalie Dartois, Nathalie Castaing, Hassan Gandjini, C. Angel Cooper

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Background: Tigecycline, an expanded broad-spectrum glycylcycline, exhibits in vitro activity against many common pathogens associated with community-acquired pneumonia (CAP), as well as penetration into lung tissues that suggests effectiveness in hospitalized CAP patients. The aim of the present study was to compare the efficacy and safety of intravenous (IV) tigecycline with IV levofloxacin in hospitalized adults with CAP. Methods: In this prospective, double-blind, non-inferiority phase 3 trial, eligible patients with a clinical diagnosis of CAP supported by radiographic evidence were stratified by Fine Pneumonia Severity Index and randomized to tigecycline or levofloxacin for 7-14 days of therapy. Co-primary efficacy endpoints were clinical response in the clinically evaluable (CE) and clinical modified intent-to-treat (c-mITT) populations at test-of-cure (Day 10-21 post-therapy). Results: Of the 428 patients who received at least one dose of study drug, 79% had CAP of mild-moderate severity according to their Fine score. Clinical cure rates for the CE population were 88.9% for tigecycline and 85.3% for levofloxacin. Corresponding c-mITT population rates were 83.7% and 81.5%, respectively. Eradication rates for Streptococcus pneumoniae were 92% for tigecycline and 89% for levofloxacin. Nausea, vomiting, and diarrhoea were the most frequently reported adverse events. Rates of premature discontinuation of study drug or study withdrawal because of any adverse event were similar for both study drugs. Conclusion: These findings suggest that IV tigecycline is non-inferior to IV levofloxacin and is generally well-tolerated in the treatment of hospitalized adults with CAP. Trial registration: NCT00081575.

Original languageEnglish
Article number44
Pages (from-to)44
Number of pages1
JournalBMC Pulmonary Medicine
Volume9
DOIs
Publication statusPublished - Sep 9 2009

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia'. Together they form a unique fingerprint.

  • Cite this

    Tanaseanu, C., Milutinovic, S., Calistru, P. I., Strausz, J., Zolubas, M., Chernyak, V., Dartois, N., Castaing, N., Gandjini, H., & Cooper, C. A. (2009). Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia. BMC Pulmonary Medicine, 9, 44. [44]. https://doi.org/10.1186/1471-2466-9-44